01—Abstract
Summary
Summary of the 8-K filed January 8, 2026. Cited figures are marked; the original filing is the authoritative source.
Illumina, Inc. (NASDAQ: ILMN) filed a Current Report on Form 8-K on January 8, 2026, to disclose management changes.
Chief Commercial Officer Everett Cunningham notified the company on January 4, 2026, that he will resign effective January 16, 2026. The company stated that Cunningham has been appointed CEO of a life science tools company. In the accompanying press release (Exhibit 99.1), Illumina announced the appointment of Eric D.
Green, M.D., Ph.D., as Chief Medical Officer, effective February 2, 2026. Dr. Green will report to the CEO and join the Executive Leadership Team. The release notes that he served as NHGRI Director from 2009 to 2025 after more than three decades at the National Human Genome Research Institute.
CEO Jacob Thaysen will serve as interim Chief Commercial Officer until a permanent successor is named. The filing also notes that Thaysen will speak at the J.P.
Morgan Healthcare Conference on Tuesday, January 13, 2026, at 7:30 AM Pacific Time. The filing does not include financial results or quantitative guidance.
02—Key points
Key Highlights
- Chief Commercial Officer Everett Cunningham will resign effective January 16, 2026, after notifying the company on January 4, 2026.
- Cunningham has been appointed CEO of a life science tools company, according to the press release.
- Eric D. Green, M.D., Ph.D., former NHGRI Director (2009 to 2025), will join as Chief Medical Officer effective February 2, 2026, reporting to the CEO.
- CEO Jacob Thaysen will serve as interim Chief Commercial Officer until a permanent successor is named.
- Dr. Green will be part of the Executive Leadership Team and will advance clinical use of genomics and expand access to precision medicine solutions.
- Thaysen is scheduled to speak at the J.P. Morgan Healthcare Conference on January 13, 2026, at 7:30 AM Pacific Time.
- The filing contains no financial results or quantitative guidance.
03—Questions
Frequently Asked Questions
Why is Illumina's Chief Commercial Officer leaving?
The filing states that Everett Cunningham notified the company on January 4, 2026, that he will resign effective January 16, 2026. The press release says he has been appointed CEO of a life science tools company. The filing does not give further reasons for his departure.
Who will lead Illumina's commercial organization after Cunningham leaves?
CEO Jacob Thaysen will act as interim Chief Commercial Officer until a permanent successor to Cunningham is named. The filing does not give a timeline for that appointment.
Who is Illumina's new Chief Medical Officer?
Eric D. Green, M.D., Ph.D., will become Chief Medical Officer effective February 2, 2026. He reports to the CEO and is part of the Executive Leadership Team. The press release says he served as NHGRI Director from 2009 to 2025 and spent more than three decades at the National Human Genome Research Institute.
What do these management changes mean for Illumina's strategy?
The press release says Dr. Green will help advance the clinical use of genomics, expand access to precision medicine solutions, and increase the diversity of genomics data. CEO Jacob Thaysen said the company has strong leadership in place and is confident in its progress toward long-term goals. The filing does not quantify any strategic or financial impact.
When will Illumina's CEO discuss the company publicly?
Jacob Thaysen is scheduled to speak at the J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 7:30 AM Pacific Time.
04—Continue